GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » 3-Year Book Growth Rate

MDXXF (Pharmala Biotech Holdings) 3-Year Book Growth Rate : -13.10% (As of Nov. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings 3-Year Book Growth Rate?

Pharmala Biotech Holdings's Book Value per Share for the quarter that ended in Nov. 2024 was $0.01.

During the past 12 months, Pharmala Biotech Holdings's average Book Value per Share Growth Rate was 25.00% per year. During the past 3 years, the average Book Value per Share Growth Rate was -13.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 4 years, the highest 3-Year average Book Value per Share Growth Rate of Pharmala Biotech Holdings was -13.10% per year. The lowest was -13.10% per year. And the median was -13.10% per year.

Competitive Comparison of Pharmala Biotech Holdings's 3-Year Book Growth Rate

For the Biotechnology subindustry, Pharmala Biotech Holdings's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's 3-Year Book Growth Rate falls into.


;
;

Pharmala Biotech Holdings 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Pharmala Biotech Holdings  (OTCPK:MDXXF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Pharmala Biotech Holdings 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » 3-Year Book Growth Rate
Comparable Companies
XCNQ:TELI XCNQ:PHRM TSXV:SBM TSX:BCT XCNQ:PREV TSXV:KNE TSX:CSCI XCNQ:BIOV TSXV:HEM TSX:RVX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
MDMA:Canada
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Website
https://www.pharmala.ca
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.